This year's meeting will focus on forging new solutions for economic, health, climate, and humanitarian issues.

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...